Measurement of faecal calprotectin concentration is increasingly used to assess disease activity in patients with IBD. Lasson et al. have now demonstrated that calprotectin concentrations in faeces of patients with mild or moderate left-sided or extensive ulcerative colitis vary considerably and have questioned the long-term stability of calprotectin when stored at room temperature.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Rheenen, P. F., van de Vijver, E. & Fidler, V. Fecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, 341, c3369 (2010).
Schoepfer, A. M. et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm. Bowel Dis. 19, 332–341 (2013).
Roseth, A. G., Fagerhol, M. K., Aadland, E. & Schjønsby, H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 27, 793–798 (1992).
Lasson, A. et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J. Crohns Colitis http://dx.doi.org/10.1016/j.crohns.2014.06.002.
Moum, B., Jahnsen, J. & Bernklev, T. Fecal calprotectin variability in Crohn's disease. Inflamm. Bowel Dis. 16, 1091–1092 (2010).
Naismith, G. D. et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment. Pharmacol. Ther. 37, 613–621 (2013).
García-Sánchez, V. et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J. Crohns Colitis 4, 144–152 (2010).
De Vos, M. D. et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm. Bowel Dis. 19, 2111–2117 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Burri, E., Beglinger, C. Faecal calprotectin testing—the need for better standardization. Nat Rev Gastroenterol Hepatol 11, 583–584 (2014). https://doi.org/10.1038/nrgastro.2014.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.154
This article is cited by
-
Redox-active nanoparticles for inflammatory bowel disease
Nano Research (2021)
-
Clinical Utility of Biomarkers in IBD
Current Gastroenterology Reports (2015)